he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看离散地址
下一页:一文依靠癫痫用药宝典
- 2022-05-04人工胰腺技术,帮助糖尿病幼儿回归正常生活
- 2022-04-252013年国际抗癫痫协会抗癫痫药使用指南
- 2022-04-25咳嗽敏感性哮喘诊断 从标准中明显可知
- 2022-04-21癫痫患者的饮食须知有什么
- 2019-04-17湖南癫痫病医院哪里好
- 预测癫痫患者再入院风险
- 结核性宫颈炎有哪些症状?
- 月经性癫痫患者妊娠期癫痫控制更好
- 2013国际抗癫痫联合会抗癫痫药用指南
- 癫痫猝死:凶手是谁?
- FDA批准Aptiom用于治疗患者癫痫发作
- 癫痫患者停药问题解决了吗?最新的预测模型已经发布!
- 难言之隐困扰了她40年,手术3小时让她一身轻松
- 癫痫治疗障碍仍难以克服
- 特发性癫痫大发作药物治疗的首选
- Am J Surg Pathol:年轻女性子宫内膜浆液性癌的独特分子、形态和临床特征
- 治疗脑炎后遗症的方法有哪些?
- 治疗白癜风的方法 牢记这些治疗白癜风更省钱
- 睾丸炎的症状是什么?
- 你无法想象男生挂空挡的快乐。!
- 治疗类风湿性关节炎/膝骨关节炎的专家共识
- 雷安平主任白癜风医院:白癜风病情变化会有什么症状?
- 癫痫怎样治疗?xgrb
- JAAD:介绍滤泡性湿疹
- 猛男必看 5壮阳法宝提升战斗力(2)
- 癫痫患者手术评估新型工具
- “保养”≠按摩,没事就不要乱做。这四种人不适合
- Blood:巨噬细胞Epo受体信号促进应激造血时红系的分化
- 治疗癫痫比较好的方法是什么?
- 患者饮食注意事项
- 为什么光疗能有效治疗白癜风?
- 注射激素会导致外周色素减少和萎缩
- 信达生物贝伐珠单抗生物类似药-达游同上市
- 治台好癫痫病的方法哪个好
- 猪血的做法 老少皆宜的红皮佳品(14)
- 女性发生癫痫病的因素有哪些?
- 气喘癫痫病症状主要有哪些?
- 用药癫痫病哪家医院好
- 怎么恰当诊断癫痫病?
- 癫痫病小发病症状 这些症状就是癫痫小发病
- 中国治疗癫痫病毫无疑问
- 女性癫痫病怎么治疗最慢
- 老人能吃橄榄菜吗 橄榄菜饭团想到
- 鲹寿司 鲹不一样的吃法
- 小孩癫痫病肉什么食物对病情好